State Key Laboratory of Chemical Resource Engineering, Key Laboratory of Carbon Fiber and Functional Polymers (Beijing University of Chemical Technology), Ministry of Education, Beijing Laboratory of Biomedical Materials, Beijing Advanced Innovation Center for Soft Matter Science and Engineering, Beijing University of Chemical Technology, Beijing, 100029, China.
Key Laboratory of Remodeling-Related Cardiovascular Diseases (Ministry of Education), and Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Beijing Anzhen Hospital Affiliated to Capital Medical University, Beijing, 100029, China.
Nat Commun. 2019 Jul 18;10(1):3184. doi: 10.1038/s41467-019-11068-1.
Thoracic aortic dissection (TAD) is an aggressive vascular disease that requires early diagnosis and effective treatment. However, due to the particular vascular structure and narrowness of lesion location, there are no effective drug delivery systems for the therapy of TAD. Here, we report a multifunctional delivery nanosystem (TP-Gd/miRNA-ColIV) composed of gadolinium-chelated tannic acid (TA), low-toxic cationic PGEA (ethanolamine-aminated poly(glycidyl methacrylate)) and type IV collagen targeted peptide (ColIV) for targeted nucleic acid therapy, early diagnosis and noninvasive monitoring of TAD. Such targeted therapy with miR-145 exhibits impressive performances in stabilizing the vascular structures and preventing the deterioration of TAD. After the treatment with TP-Gd/miR-145-ColIV, nearly no dissection occurs in the thoracic aortic arches of the mice with TAD model. Moreover, TP-Gd/miRNA-ColIV also demonstrates good magnetic resonance imaging (MRI) ability and can be used to noninvasively monitor the development conditions of TAD.
胸主动脉夹层(TAD)是一种侵袭性血管疾病,需要早期诊断和有效治疗。然而,由于血管结构的特殊性和病变位置的狭窄,目前还没有有效的药物输送系统用于 TAD 的治疗。在这里,我们报告了一种多功能递药纳米系统(TP-Gd/miRNA-ColIV),由钆螯合物单宁酸(TA)、低毒阳离子 PGEA(乙醇胺-氨基聚(甲基丙烯酸缩水甘油酯))和 IV 型胶原靶向肽(ColIV)组成,用于靶向核酸治疗、TAD 的早期诊断和无创监测。用 miR-145 进行靶向治疗在稳定血管结构和防止 TAD 恶化方面表现出令人印象深刻的效果。在用 TP-Gd/miR-145-ColIV 治疗后,TAD 模型小鼠的胸主动脉弓几乎没有发生夹层。此外,TP-Gd/miRNA-ColIV 还具有良好的磁共振成像(MRI)能力,可用于无创监测 TAD 的发展情况。